The drug is a phosphate binder and is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus.
The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 296 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY2003-04.
Cadila Healthcare Ltd is currently trading at Rs387.40, up by Rs2.1 or 0.55% from its previous closing of Rs385.30 on the BSE. The scrip opened at Rs395 and has touched a high and low of Rs395.05 and Rs385.50 respectively.